Icon books record earnings for Q2 as business wins soar

Irish CRO Icon ($ICLR) made a strong showing in the second quarter as revenue and bookings jumped for the company.

The Dublin-headquartered CRO said gross business wins in the second quarter were a record $622 million.

When this was lowered by cancellations in the quarter, which took off $120 million, it still posted a record net business wins of $502 million--a net book-to-bill of 1.22.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

The company’s CFO Brendan Brennan said in a webcast about its earnings that the main driver of the cancellations was from a termination of a single, large oncology trial a due to safety and efficacy concerns. Further details were not shared.

He noted that the $120 million cancellations fee was higher than previous quarters, but still within its historic range.

Net revenue for the past three months grew 5.7% year-on-year to $410.6 million with income from operations jumping 14.5% to $78 million. For the half, sales for 2016 increased by 4.4% to $811.2 million.

Guidance for the full year has been updated with earnings reaffirmed in the range of $4.60 - $4.80 and revenue revised to a range of $1.66 billion to $1.68 billion.

The company said it had also added around 100 new staff in the quarter.

CEO Ciaran Murray said: “Through a consistent focus on our strategic plan we achieved a record level of net business awards of $502 million and grew our backlog by almost 9% over last year.

“We delivered record revenue of $411 million and grew earnings per share by 20% to $1.14. We are reaffirming our 2016 earnings guidance to be in the range of $4.60 to $4.80.”

This follows on from its strong 2015 full-year showing, that saw its revenue jumping by 10% at CER, reaching $1.57 billion.

The CRO has also been busy racking up the deals, including a recent tie-up with Genomics England and IBM Watson ($IBM), as well as the takeover of MediMedia Pharma Solutions and the buyout of PMG Research.

The CRO closed up 4.4% after releasing its results yesterday.

- listen to Icon’s recorded Q2 webcast
- see the CRO’s Q2 statement

Related Article:
New Pfizer deals with Icon, Parexel allay worries over CRO cuts


Suggested Articles

Clinical trial firm Phesi’s new report is some grim reading for the life science industry: Studies for new drugs are still suffering.

Tempus fugit: And time especially flies when it comes clinical trials. Covance is teaming up with the suitably named Tempus to clip its wings.

PPD has raised its quarterly guidance after weathering the COVID-19 storm and is immediately making a secondary offering of 38 million shares.